Drug
Enavogliflozin clinical trials
Also written DWP16001.
- studies test it
- 33
- open now
- 14
- in phase 3
- 10
- first study started
- 2017
Keep track of what changes. Save the Enavogliflozin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- DWP16001
- 17
Combined with it in one product
Studies by the year they started
33 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 1
- Phase 3
- 10
- Phase 4
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 8
Daewoong Pharmaceutical Co. LTD. (25) · Yonsei University (3) · Asan Medical Center (1) · Duk-Woo Park, MD (1) · Seoul St. Mary's Hospital (1) · Seoul National University Bundang Hospital (1) · Korea University Anam Hospital (1)
Often tested with
Tested in the same studies.
DWC202511 (1) · DWC202512 (1) · DWJ1525 (1) · DWC202101 (1) · Metformin (1) · DWC202518 (1) · DWC202407 (1) · DWC202408 (1)
Studies
Open first, then newest update. How each study uses Enavogliflozin is read from its arms, and is right about nine times in ten.
Testing it · 33
- ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve ReplacementRecruitingPhase 4Duk-Woo Park, MDNCT05672836Written as Enavogliflozin
- Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThyRecruitingPhase 4Seoul St. Mary's HospitalNCT07240844Written as Enavogliflozin 0.3mg
- To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes MellitusNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT07619833Written as DWP16001
- Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter AblationRecruitingPhase 4Yonsei UniversityNCT06528262Written as Enavogliflozin
- Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisRecruitingPhase 4Seoul National University Bundang HospitalNCT06399835Written as Enavogliflozin
- Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in ObesityRecruitingPhase 4Korea University Anam HospitalNCT06782139Written as Enavogliflozin
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathyRecruitingPhase 4Yonsei UniversityNCT06580717Written as enavogliflozin 0.3mg
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy AdultsNot yet recruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT06644404Written as DWP16001 0.3mg
- A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus PatientsRecruitingPhase 4Yonsei UniversityNCT06642623Written as Enavogliflozin
- Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT06606093Written as DWP16001 0.3mg
- A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusRecruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT05466643Written as DWP16001 0.3mg
- To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic FunctionRecruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT05747664Written as DWP16001
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes MellitusNot yet recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT06141980Written as DWP16001 0.3 mg
- To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult VolunteersRecruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT05797922Written as DWP16001
- Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy AdultsCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT07213310Written as DWP16001
- Enavogliflozin Outcome Trial in Functional Tricuspid RegurgitationActive, not recruitingPhase 3Asan Medical CenterNCT06027307Written as Enavogliflozin
- The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminActive, not recruitingPhase 3Daewoong Pharmaceutical Co. LTD.NCT05505994Written as DWP16001
- To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose CombinationStatus unknownPhase 1Daewoong Pharmaceutical Co. LTD.NCT05737771Written as DWP16001
- Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and CCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT05465668Written as DWP16001 Drug A
- The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.CompletedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04632862Written as DWP16001
Codes
What other systems call Enavogliflozin · ClinicalTrials.gg INT002065
- MeSH (NLM) C000729921EnavogliflozinOne source ClinicalTrials.gov
- UNII (FDA) Z5MR2Y1IJJENAVOGLIFLOZINConfirmed FDA, Wikidata
- Wikidata Q123598885enavogliflozinConfirmed FDA, Wikidata
- NCI Thesaurus C171901EnavogliflozinOne source FDA
- DrugBank DB18970One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729921 | Enavogliflozin | One source ClinicalTrials.gov |
| UNII (FDA) | Z5MR2Y1IJJ | ENAVOGLIFLOZIN | Confirmed FDA, Wikidata |
| Wikidata | Q123598885 | enavogliflozin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171901 | Enavogliflozin | One source FDA |
| DrugBank | DB18970 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.